Articles from MediWound Ltd.

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, 2025 at 8:00 AM ET. To attend the virtual fireside chat, please register here.

YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx®, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phase III VALUE study in venous leg ulcers (VLUs) and EscharEx’s commercial opportunity.

EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025

Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes

YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET.

YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, on Tuesday, September 10, 2024 at 3:30 p.m. ET at the H.C. Wainwright 26th Annual Global Investment Conference.

Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages

Completed Construction of New NexoBrid® Manufacturing Facility

NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients

Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time

Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue

Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs)

Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment

 NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year

Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time

Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing

$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to begin Phase III in the second half of 2024$42 million cash runway through profitability

Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time

Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU)

YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.

If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.

Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million

Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement

NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound.

Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time

The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all ages

NexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients

MediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers

YAVNE, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently concluded 20th European Burns Association (EBA) Congress held in Nantes, France on September 6-9, 2023.

YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming H.C. Wainwright 25th Annual Global Investment Conference. The conference will take place in New York City and virtually from September 11-13, 2023.

EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders

MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers

MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers

Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time

Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement

MW005 shown to be safe and well-tolerated

Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers

YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest. The conference will take place online from June 20 to June 22, 2023.

On track to initiate EscharEx® Phase III study in fourth quarter 2023NexoBrid® U.S. launch expected in early third quarter 2023Cash of over $57 million; Operating cash runway through profitability

Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time

Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension

Data to be highlighted in oral and poster presentations

2022 total revenues of $26.5 million

YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition.

Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development

Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time

YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQMDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced management will present at two upcoming investor conferences in March. Details for each is as follows:

YAVNE, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQMDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct offering. The gross proceeds to the Company from the offering were $27.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx®, establishing a U.S. commercial presence, supporting business development activities, and for general corporate purposes. The Company may also use a portion of the net proceeds to in-license, invest in or acquire businesses, technologies, products or assets that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions or in-licenses at this time.

YAVNE, Israel, Feb. 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQMDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement for the sale and purchase of1,964,286 shares of the Company’s ordinary shares, par value NIS 0.07, at a purchase price of $14 per share, in a registered direct offering. The Company expects to close the offering on or about February 7, 2023, subject to the satisfaction of customary closing conditions.

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns

Japan is the first country in the world to approve NexoBrid for people of all ages; pediatric and adult populations

NexoBrid gained marketing approval in Switzerland; launch expected first quarter 2023

MW005 shown to be safe and well-tolerated

Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company

YAVNE, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound” or the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it intends to effect a 1-for-7 reverse share split of its ordinary shares. Subject to the Company’s satisfaction of Nasdaq Operations notice requirements, the scheduled effective date is December 20, 2022, with trading on a reverse split-adjusted basis to begin at market open on that day. Trading of the Company’s ordinary shares will continue on the Nasdaq Global Market under the symbol “MDWD,” but the shares will trade under the new CUSIP number, M68830112. In the event of a delay in the effective date, the Company will update the public via a subsequent press release.

Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time

Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities

EscharEx’s promising results from the completed Phase 2 trials were highlighted

Gross Proceeds of $30.5 Million Raised